Blueprint Medicines (NASDAQ:BPMC) Earns Market Outperform Rating from JMP Securities
JMP Securities reiterated their market outperform rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports. The brokerage currently has a $114.00 price target on the biotechnology company’s stock. Other analysts have also recently issued reports about the company. Wedbush restated an outperform […]
More Stories
Putin Backs Trump’s Peace Effort, Says Russia Accepted Compromises
By Guy Birchall Russian President Vladimir Putin, speaking during his marathon annual news conference on Dec. 19, said he supports...
Ford Recalls Nearly 273,000 Vehicles Over Rollaway Risk
By Rob Sabo Ford Motor Company has announced the recall of 272,645 vehicles over concerns that the automobiles could roll...
Trump Unveils Deals With 9 Pharma Companies to Reduce Drug Prices
By Travis Gillmore WASHINGTON—President Donald Trump announced agreements with nine of the largest pharmaceutical companies to offer drugs to Americans...
White House Economist Predicts ‘Biggest Refund Cycle Ever’ During 2026 Tax Season
By Jack Phillips The White House’s National Economic Council director predicted the largest-ever tax “refund cycle” in 2026 as several...
EU Leaders Agree to Explore Use of Frozen Russian Assets for Ukraine
By Guy Birchall European Union leaders agreed at a summit in Brussels on Dec. 18 to explore financing Ukraine’s 2026–27...
Small Plane Crashes Into New Hampshire Condominiums
By The Associated Press NASHUA, N.H.—A pilot was taken to the hospital with injuries Wednesday after a small plane crashed...